Regenicin (Regenicin) Total Liabilities : $18.07 Mil (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Total Liabilities?

Regenicin's Total Liabilities for the quarter that ended in Mar. 2023 was $18.07 Mil.

Regenicin's quarterly Total Liabilities increased from Sep. 2022 ($5.61 Mil) to Dec. 2022 ($17.67 Mil) and increased from Dec. 2022 ($17.67 Mil) to Mar. 2023 ($18.07 Mil).

Regenicin's annual Total Liabilities increased from Sep. 2020 ($4.29 Mil) to Sep. 2021 ($4.96 Mil) and increased from Sep. 2021 ($4.96 Mil) to Sep. 2022 ($5.61 Mil).

Regenicin Total Liabilities Historical Data

The historical data trend for Regenicin's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Total Liabilities Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Total Liabilities

Get a 7-Day Free Trial

3.06

3.73

4.29

4.96

5.61

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Liabilities	Get a 7-Day Free Trial															5.28	5.44	5.61	17.67	18.07

Regenicin Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regenicin's Total Liabilities for the fiscal year that ended in Sep. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.613	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	5.61

Total Liabilities	=	Total Assets (A: Sep. 2022 )	-	Total Equity (A: Sep. 2022 )
	=	0.015	-	-5.597
	=	5.61

Regenicin's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18.07	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	18.07

Total Liabilities	=	Total Assets (Q: Mar. 2023 )	-	Total Equity (Q: Mar. 2023 )
	=	11.859	-	-6.211
	=	18.07

Regenicin Total Liabilities Related Terms

Thank you for viewing the detailed overview of Regenicin's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines